Highlights
- 1
- 2Cancer cell · 2020
- 3Journal of clinical microbiology · 2020
Publications
203 publications
Funding
22 grants
Active
8 grants- Sub-PIBactericidal Hydrogels for Bone RepairNational Inst of Arthritis & Musculoskeletal & Skin Diseases · 2024–2029 · via Georgia Institute of TechnologyR01AR083702-03
- Sub-PIDevelopment of Targeted Antipseudomonal Bactericidal ProdrugsNational Institute of Allergy and Infectious Diseases · 2023–2028 · via Cornell University - IthacaR01AI174461-04
- PIHardy Diagnostics and NG Biotech NG-TEST® Candida auris Research AgreementHardy Diagnostics · 2026–2027ContractHD 263836-01
- Sub-PICombatting Hospital-Acquired Carbapenem-Resistant Organism Infections in CatsEveryCat Health Foundation · 2026–2027 · via Cornell UniversityCU 256123-01
- Co-IScreening for Fluoroquinolone-Resistant Viridans Group Streptococci to Individualize Infection Prevention Strategies in Neutropenic PatientsNational Institute of Allergy and Infectious Diseases · 2024–2027R21AI182845-02
- Co-IIn vitro Activity of Delafloxacin Against Viridians Group Streptococci Isolated from Neutropenic PatientsMelinta Therapeutics, Inc. · 2026–2026ContractSRA 253345-01
- Co-I"Multi-Drug Resistant Organism Network" (MDRO NETWORK)National Institute of Allergy and Infectious Diseases · 2019–2026 · via Duke UniversityUM1AI104681-08
- Co-IMetagenomic profiling of urinary cell-free DNA to monitor urinary tract infection after kidney transplantationNational Institute of Allergy and Infectious Diseases · 2020–2026 · via Cornell University - IthacaR01AI151059-02
Completed grants (14)
- Co-IScreening for Resistant Enteric Bacteria to Personalize Infection Prevention Strategies in Neutropenic PatientsNational Institute of Allergy and Infectious Diseases · 2020–2025R01AI151038-04
- PI"Performance comparison of rapid Antimicrobial Susceptibility Test (AST) system for clinical isolate colonies" SRA with Selux DiagnosticsSelux Diagnostics · 2022–2024ContractSA 225932-01
- PIHardy/NG Biotech CTX-M StudyHardy Diagnostics · 2023–2024ContractSA 233773-01
- Co-ICell-Free DNA in Peritoneal Fluid as a Novel and Versatile Analyte for Monitoring PeritonitisNational Institute of Allergy and Infectious Diseases · 2021–2024R21AI164093-01
- PIClinical utility of viral load quantification in influenza infectionsCornell University - Ithaca · 2022–2023CU 228234-01
- Co-IPredicting Infections in Neutropenic Hosts Receiving Fluoroquinolone ProphylaxisNational Institute of Allergy and Infectious Diseases · 2020–2023
- Co-IDETECTION OF IMPENDING INFECTIONS IN IMMUNOCOMPROMISED CANCER PATIENTS.Starr Cancer Consortium · 2020–2022I13-0013
- Sub-PITargeted Macromolecular Antimicrobial Prodrugs against Pseudomonas aeruginosaNational Institute of Allergy and Infectious Diseases · 2020–2022 · via Cornell University - IthacaR21AI154102-02
- PIMulticenter Evaluation of Detection of SARS-CoV-2 on the cobas® Liat® SystemRoche Molecular Systems, Inc. · 2020–2022ContractSRA 204685-01
- PIPerformance Evaluation of the LifeScale AST Rapid, Automated Antimicrobial Susceptibility SystemAffinity Biosensors LLC · 2020–2022ContractSRA 201975-01
- PIDetermining the role of antibiotic tolerance in antibiotic therapy failureWeill Cornell Medical College · 2021–2021WCMC 211765-01
- Co-IMultiplex PCR Characterization of Gastrointestinal Pathogens in Immunosuppressed Transplant PatientBioFire Diagnostic, LLC · 2018–2021SRA 181751-01
- Co-Icobas® vivoDx MRSA Early Evaluation Program (EEP)Roche Molecular Systems, Inc. · 2020–2021ContractSRA 202240-01
- Co-IPeritoneal Fluid Microbiome Predictive of PeritonitisNational Kidney Foundation, Inc. · 2017–2019NKF 17091294-01
External relationships
Advisory/Scientific Board Member
Shionogi & Co., Ltd